Skip to main content

Table 2 Positivity rate for methylated BCAT1, IKZF1 and IRF4 in each clinical phenotype

From: Evaluation of a panel of tumor-specific differentially-methylated DNA regions in IRF4, IKZF1 and BCAT1 for blood-based detection of colorectal cancer

 

N

BCAT1

IKZF1

IRF4

n, Posa (%, 95% CI)

OR (95% CI)b

n, Pos. (%, 95% CI)

OR (95% CI)

n, Pos. (%, 95% CI)

OR (95% CI)

All cases

1620

173 (10.7, 9–12)

–

185 (11.4, 10–13)

–

138 (8.5, 7–9)

–

Cancer

184

87 (47.3, 40–55)

15.8 (10–24)*

109 (59.2, 52–66)

32.6 (21–51)*

92 (50.0, 43–57)

44.6 (26–77)*

Early stage

98

38 (38.8, 29–49)

11.2 (7–19)*

51 (52.0, 42–62)

24.3 (15–41)*

40 (40.8, 31–51)

30.7 (17–56)*

Late stage

84

48 (57.1, 46–68)

23.5 (14–40)*

56 (66.7, 56–77)

44.9 (26–80)*

50 (59.5, 48–70)

65.5 (35–124)*

Stage I

41

8 (19.5, 10–34)

4.3 (2–10)*

11 (26.8, 13–41)

8.2 (4–18)*

7 (17.1, 5–29)

9.2 (4–23)*

Stage II

57

30 (52.6, 40–65)

19.6 (11–35)*

40 (70.2, 58–82)

52.8 (27–99)*

33 (57.9, 45–71)

61.3 (30–122)*

Stage III

51

23 (45.1, 33–59)

14.5 (8–27)*

33 (64.7, 51–78)

41.1 (21–81)*

28 (54.9, 41–69)

54.2 (27–112)*

Stage IV

33

25 (75.8, 59–87)

55.1 (24–121)*

23 (69.7, 53–86)

51.6 (23–114)*

22 (66.7, 50–84)

89.1 (36–209)*

Unstaged

2

1 (50.0, 3.–97)

17.6 (91–335)

 

–*

2 (100, 16–100)

–*

Adenoma

616

42 (6.8, 5–9)

1.3 (1–2)

41 (6.7, 5–9)

1.6 (1–3)

28 (4.5, 3–6)

2.1 (1–4)*

Advanced

337

29 (8.6, 6–12)

1.7 (1–3)*

29 (8.6, 6–12)

1.7 (1–3)*

20 (5.9, 3–9)

2.8 (2–5)*

Non-advanced

279

13 (4.7, 3–8)

0.7 (0.5–2)

12 (4.3, 2–7)

1.0 (0.5–2)

8 (2.9, 1–5)

1.3 (0.6–3)

HGDc

35

5 (14.3, 6–30)

2.9 (1–8)*

6 (17.1, 8–33)

4.6 (2–12)*

7 (20.0, 10–36)

11.1 (4–29)*

LGDc

549

35 (6.4, 5–9)

1.2 (0.7–1.9)

32 (5.8, 4–8)

1.4 (1–2)

18 (3.3, 2–5)

1.5 (0.8–3)

No Neoplasia

820

44 (5.4, 4–7)

Ref

35 (4.3, 3–6)

Ref

18 (2.2, 1–3)

Ref

Non-neoplastic pathologiesd

252

14 (5.6, 3–8)

–

9 (3.6, 1–6)

–

10 (4.0, 2–6)

–

Healthy colon

568

30 (5.3, 3–7)

–

26 (4.6, 3–6)

–

8 (1.4, 0.4–2)

–

  1. aAt least one PCR replicate positive for DNA methylation
  2. bOdds ratio (95% CI) compared to cases without neoplasia (Ref), *p values < 0.05
  3. cThe severity of dysplasia was available for 584 of 616 adenomas; HGD, high grade dysplasia; LGD, low grade dysplasia
  4. dBenign polyps (hyperplastic, unspecified, inflammatory, other polyps), inflammatory bowel disease, diverticular disease, angiodysplasia, hemorrhoids
Back to article page

Clinical Epigenetics

ISSN: 1868-7083

Contact us